+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the clinical and endoscopic effects of guselkumab in children aged 2 to 17 with moderately to severely active Crohns Disease who responded to the treatment by Week 12. The study aims to assess the benefits of guselkumab after one year of maintenance therapy. This is a Phase 3 trial sponsored by Janssen Research & Development, LLC. Participants initially receive guselkumab either intravenously or subcutaneously according to their body weight during a 12-week open-label induction phase. Those who respond by Week 12 are then randomly assigned to one of two guselkumab subcutaneous dosing regimens for a double-blind maintenance phase lasting up to Week 48. Participants who do not respond by Week 12 enter an open-label maintenance phase receiving guselkumab subcutaneously up to Week 48. Throughout the study, participants undergo clinical evaluations, endoscopic assessments, and measurement of guselkumab levels at regular intervals up to Week 52. Researchers monitor changes in clinical remission, endoscopic response, growth parameters such as height and weight, and record any adverse events up to Week 64. The total participation duration extends to approximately one year, with ongoing safety and efficacy assessments.

Age: 2Years - 17YearsAll GendersPhase 3
85 locations
E

Actively Recruiting

Researchers are evaluating GB-0895 as an add-on therapy for adolescents and adults with severe asthma that remains uncontrolled despite using inhaled corticosteroids and other asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the effectiveness and safety of GB-0895 in improving asthma outcomes. Participants will receive either GB-0895 or a placebo through subcutaneous injections every six months during the treatment period. The study includes a screening and run-in phase from weeks -5 to 0, a treatment phase lasting 52 weeks, and a follow-up phase lasting from week 52 to week 90. An optional open-label extension allows continued GB-0895 treatment from week 52 through week 142. During the study, participants will undergo various assessments including lung function tests, questionnaires about asthma symptoms and quality of life, and monitoring for asthma exacerbations and adverse events. Researchers will measure outcomes such as the annual rate of asthma exacerbations and changes in lung function over 52 weeks. Safety evaluations will continue throughout treatment and follow-up. The total participation duration may extend up to nearly three years if the optional extension is chosen.

Age: 12Years - 80YearsAll GendersPhase 3
158 locations
A

Actively Recruiting

Researchers are evaluating the effects of AZD6793 in adults with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase IIb study compares two different doses of AZD6793 to placebo tablets to assess their efficacy and safety. The study is randomized, double-blind, placebo-controlled, and involves about 970 participants worldwide. Participants will be randomly assigned to one of three groups two different doses of AZD6793 or a matching placebo. The study lasts for 24 weeks, during which participants will take oral tablets of their assigned treatment. The trial aims to measure how well AZD6793 works to reduce COPD exacerbations compared to placebo. Throughout the study, participants will have regular assessments including lung function tests, symptom questionnaires, and blood tests to measure drug levels. Researchers will monitor the rate of COPD exacerbations, lung function changes, and symptom scores over 24 weeks. Safety and tolerability of the treatments will also be closely observed during this period.

Age: 40Years +All GendersPhase 2
367 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease COPD who are already receiving inhaled maintenance therapy and have experienced recent COPD exacerbations. This Phase 3, multicenter, randomized, double-blind, placebo-controlled study aims to understand how tezepelumab impacts COPD outcomes compared to a placebo. Participants will receive monthly subcutaneous injections of one of two doses of tezepelumab or a matching placebo. The treatment period lasts a minimum of 52 weeks and up to 76 weeks. Following treatment, there is a 12-week safety follow-up without active treatment to monitor participants. Throughout the study, participants will be monitored regularly to assess lung function, COPD symptoms, and exacerbation rates. Researchers will collect data on lung function tests, symptom questionnaires, and exacerbation frequency up to 76 weeks. Blood samples will be taken to study drug levels and immune responses. The total participation time for each individual includes the treatment period plus the safety follow-up phase.

Age: 40Years - 80YearsAll GendersPhase 3
284 locations
A

Actively Recruiting

Healthy Volunteer

Researchers are establishing a national cohort of approximately 4,000 young adults aged 25 to 35 without severe lung disease to better understand lung health and identify early targets to prevent chronic lung disease. This observational study aims to explore how lifetime environmental exposures, physical fitness, biomarkers, and respiratory epithelial gene activity relate to ideal or impaired lung function in young adulthood. Participants undergo an initial baseline assessment including pre-bronchodilator lung function tests measuring Forced Expiratory Volume in one second FEV1 and Forced Vital Capacity FVC. After enrollment, participants will receive remote contacts via text, email, mail, or phone at regular intervals for up to 4.5 years to collect follow-up information. If funding allows, the study may be extended to observe long-term changes in lung health beyond 5 years. During the study, participants provide contact details for proxies to help maintain follow-up. Researchers will evaluate lung function and related factors through scheduled remote communications without administering treatments. The study involves ongoing monitoring and data collection over several years to understand factors influencing lung health, with total participation lasting up to at least 4.5 years and possibly longer if extended.

Age: 25Years - 35YearsAll Genders
37 locations
S

Actively Recruiting

Researchers are evaluating the drug omalizumab to see if it helps people aged 40 and older who have Chronic Obstructive Pulmonary Disease COPD and are allergic to common indoor allergens such as pet dander, cockroaches, or dust mites. This study focuses on individuals who have allergen exposure in their homes and aims to assess the rate of COPD exacerbations over 12 months. The trial is sponsored by Johns Hopkins University and is a randomized, placebo-controlled phase 2 study. Participants receive subcutaneous injections of either omalizumab or a placebo normal saline at a clinic. The dose and frequency of injections are determined by weight and blood test results, with injections given either monthly 12 doses or twice monthly 24 doses. The active treatment follows a dosing schedule similar to that used for asthma. The study includes about 1 to 3 months of screening, 12 months of receiving the study drug, and a follow-up call one month after the final clinic visit. During the trial, participants visit the clinic for their injections and are monitored for side effects after each dose. Researchers will measure how often participants experience COPD exacerbations during the 12-month treatment period. The total participation lasts about 16 months, including screening, treatment, and follow-up. Participants must continue their usual inhaled therapies, and safety is monitored throughout the study.

Age: 40Years +All GendersPhase 2
23 locations
R

Actively Recruiting

Researchers are studying Idiopathic Pulmonary Fibrosis IPF and other chronic fibrosing interstitial lung diseases ILDs with a progressive phenotype through the IPF-PRO and ILD-PRO Registries. This prospective registry collects data on the natural history, healthcare experiences, quality of life, and treatments of participants diagnosed with IPF or other chronic fibrosing ILDs. Blood samples and chest imaging studies are also gathered and stored for future research. The registry originally enrolled over 1000 participants with IPF and expanded to include other fibrosing ILDs with progressive phenotypes, aiming to enroll up to 1000 additional patients in each phase.

Age: 21Years +All Genders
47 locations
O

Actively Recruiting

Researchers are investigating how highly effective cystic fibrosis transmembrane conductance regulator CFTR modulators affect chronic rhinosinusitis CRS and problems with the sense of smell olfactory dysfunction in young children with cystic fibrosis. This observational study focuses on children aged 2 to 8 years old and compares those receiving these modulator therapies with those not receiving them. The goal is to understand if early treatment with these drugs can improve sinus and smell function in this group. The study includes two groups one group of children starting treatment with ivacaftor or elexacaftortezacaftorivacaftor known as highly effective modulator therapy or HEMT, and a control group not receiving HEMT. Participants in the HEMT group have assessments before starting therapy and at 1 and 2 years afterward. The control group undergoes the same assessments at similar intervals to track natural disease progression without treatment. Participants will undergo sinus MRI scans to measure sinus opacification and olfactory bulb volume, along with smell tests and quality of life surveys at baseline, 1 year, and 2 years. The study tracks changes in these outcomes over the two-year period. This includes specific smell tests like the Pediatric Smell Wheel and questionnaires assessing nasal symptoms and overall quality of life. The research team also monitors safety by recording any prior medication use or surgeries that may affect the results.

Age: 2Years - 8YearsAll Genders
6 locations